Lonza to invest in mid-scale API manufacturing expansion at Chinese facility
The expansion of mid-scale capacity will enable the company to offer a smooth transition between early-phase and large-scale commercial production
Lonza is investing CHF 20 million ($21.7 million) to expand its API development and manufacturing site in Nansha, China, the CDMO said on Monday.
The investments include six 1,000-L small molecule reactors, four 1,500-L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production.
New development and GMP laboratories with capabilities to manufacture small-scale batches of highly potent APIs (HPAPIs) also form part of the investment.
The expanded laboratories and manufacturing will create approximately 70 new jobs once it comes online between Q1 and Q3 next year.
Commenting on the announcement, Gordon Bates, President, Division Small Molecules, Lonza, said the planned expanded capabilities will support the increasing number of global pharma and biopharma looking to develop and manufacture products in China.
Jan Vertommen, Senior Director, Commercial Development, Lonza said the expanded facilities will provide customers with a "cost-effective" and "seamless" way to transition small molecule compounds from early to commercial phase.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance